Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

NCT02172495 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4700

Last updated 2018-08-31

No results posted yet for this study

Summary

Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Tiotropium bromide

Tiotropium bromide 18 micrograms

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2003-10-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02172495 on ClinicalTrials.gov